Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche span> par promoteur : Janssen R&D Ireland
Femme et Homme Max 99 ans
Janssen R&D Ireland
MAJ Il y a 5 ans
Early Access of TMC125 in combination with other antiretrovirals in treatment-experienced HIV-1 infected subjects with limited treatment options
The primary objective of this trial is to provide early access to TMC125 for treatment-experienced HIV-1 infected subjects who have failed multiple ARV regimens and have limited treatment options with...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Janssen R&D Ireland
MAJ Il y a 5 ans
Efficacy and Safety Study of Simeprevir in Combination with Sofosbuvir in Subjects with Chronic Genotype 4 Hepatitis C Virus Infection Estudio de la eficacia y seguridad de Simeprevir en combinación con Sofosbuvir en pacientes con infección crónica por virus de la hepatitis C genotipo 4
To show superiority of SMV (150 mg qd) in combination with SOF (400 mg qd) for 12 weeks versus a historical control, with respect to the proportion of subjects with sustained virologic response 12 we...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Janssen R&D Ireland
MAJ Il y a 5 ans
An Open-Label, Single-Arm Phase III Study to Evaluate the Efficacy, Safety and Tolerability of TMC435 in Combination With PegIFN alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naïve or Treatment-Experienced, Chronic Hepatitis C Virus Genotype-4 Infected Patients
The primary objective is to evaluate the efficacy of TMC435 in combination with PegIFNα-2a/RBV with respect to the proportion of subjects with chronic HCV-4 infection achieving SVR 12 weeks after plan...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Janssen R&D Ireland
MAJ Il y a 5 ans
TMC435-TiDP16-C216 - Phase III Trial of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Patients
The primary objective is to demonstrate the superiority of TMC435 versus placebo as part of a treatment regimen including peginterferon alpha-2a (PegIFNα-2a)/ribavirin (RBV) or PegIFNα-2b/RBV, with re...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Janssen R&D Ireland
MAJ Il y a 5 ans
The VIOLIN Study: to Evaluate etravirine Tolerability, Pharmacokinetics With Other Antiretrovirals In Treatment Experienced Patients
Main objectives: Safety: Number of participants with Adverse Events as a measure of safety and tolerability Tolerability: Number of participants with Adverse Events as a measure of safety and to...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Janssen R&D Ireland
MAJ Il y a 5 ans
Study to Evaluate Efficacy of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected Participants
The purpose of this study is to demonstrate non-inferiority in efficacy while switching to a once-daily single-tablet regimen containing darunavir (DRV)/ cobicistat (COBI)/ emtricitabine (FTC)/ tenofo...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Précédent
1
2